GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Price-to-Free-Cash-Flow

Revvity (Revvity) Price-to-Free-Cash-Flow

: 1,061.68 (As of Today)
View and export this data going back to 1983. Start your Free Trial

As of today (2024-04-19), Revvity's share price is $100.86. Revvity's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.10. Hence, Revvity's Price-to-Free-Cash-Flow Ratio for today is 1,061.68.

The historical rank and industry rank for Revvity's Price-to-Free-Cash-Flow or its related term are showing as below:

RVTY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.68   Med: 26.44   Max: 1166.32
Current: 1061.73

During the past 13 years, Revvity's highest Price-to-Free-Cash-Flow Ratio was 1166.32. The lowest was 11.68. And the median was 26.44.

RVTY's Price-to-Free-Cash-Flow is ranked worse than
98.9% of 91 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.86 vs RVTY: 1061.73

Revvity's Free Cash Flow per Share for the three months ended in Dec. 2023 was $1.40. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.10.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Revvity was -98.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -78.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -32.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -2.90% per year.

During the past 13 years, Revvity's highest 3-Year average Free Cash Flow per Share Growth Rate was 79.80% per year. The lowest was -840.20% per year. And the median was 1.00% per year.


Revvity Price-to-Free-Cash-Flow Historical Data

The historical data trend for Revvity's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.38 19.41 17.71 29.83 1,383.67

Revvity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.83 44.29 98.74 - 1,383.67

Competitive Comparison

For the Diagnostics & Research subindustry, Revvity's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity Price-to-Free-Cash-Flow Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Revvity's Price-to-Free-Cash-Flow falls into.



Revvity Price-to-Free-Cash-Flow Calculation

Revvity's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=100.86/0.095
=1,061.68

Revvity's Share Price of today is $100.86.
Revvity's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Revvity  (NYSE:RVTY) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Revvity Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Revvity's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121

Revvity (Revvity) Headlines

From GuruFocus

Q3 2023 Revvity Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Revvity Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 PerkinElmer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024